Florian Anca, Ludwig Anna, Rösch Sabine, Yildiz Handan, Klumpp Siegfried, Sechtem Udo, Yilmaz Ali
Department of Cardiology and Angiology, University Hospital Münster, Münster, Germany.
Division of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Int J Cardiol. 2014 May 1;173(2):184-9. doi: 10.1016/j.ijcard.2014.02.016. Epub 2014 Feb 22.
This study investigated the safety profile and potential "therapeutic" effect of intravenous ultrasmall superparamagnetic iron-oxide (USPIO)-based iron administration regarding infarct healing in patients with ST-elevation myocardial infarction (STEMI). USPIO-administration was recently shown to enable an improved characterization of myocardial infarct pathology in acute STEMI patients.
Seventeen study patients (IRON, 54 ± 9 yrs, 88% male) and 22 matched controls (CONTROL, 57 ± 9 yrs, 77% male) both with primary reperfused STEMI underwent multi-parametric CMR studies in the first week and three months after acute MI. Only IRON patients received a single intravenous bolus of 510 mg elemental iron as ferumoxytol (Feraheme(TM)) within four days following acute MI.
Three months later, all patients were alive and there were no adverse cardiac events. Significant improvement in left ventricular (LV) ejection fraction (IRON: 53 ± 10% to 59 ± 9%, p=0.002;
54 ± 6% to 57 ± 10%, p=0.005) as well as shrinkage of infarct size were seen in both groups at follow-up. There was a more pronounced decrease in infarct size in the IRON group (IRON: -10.3 ± 5.4% vs.
-7.0 ± 8.4%, p=0.050) in addition to a significant decrease in both endocardial extent and prevalence of transmural infarctions in IRON but not in CONTROL patients. A significant decrease in LV end systolic volume was only seen in the IRON group (71 ± 25 mL to 59 ± 25 mL, p=0.002).
Intravenous iron administration in acute STEMI patients seems to be associated with an improved infarct healing and a beneficial global left ventricular remodelling. These findings together with the good safety profile make USPIO-based iron administration a promising future candidate as a "diagnostic" and "therapeutic" adjunctive solution in acute MI management.
本研究调查了静脉注射基于超小超顺磁性氧化铁(USPIO)的铁剂对ST段抬高型心肌梗死(STEMI)患者梗死愈合的安全性及潜在“治疗”效果。最近有研究表明,给予USPIO能够改善急性STEMI患者心肌梗死病理特征的表征。
17例研究患者(IRON组,年龄54±9岁,男性占88%)和22例匹配的对照患者(CONTROL组,年龄57±9岁,男性占77%)均为首次再灌注的STEMI患者,在急性心肌梗死(MI)后的第一周和三个月接受了多参数心脏磁共振成像(CMR)研究。仅IRON组患者在急性MI后4天内接受了一次静脉推注510mg元素铁(以蔗糖铁形式,商品名Feraheme™)。
三个月后,所有患者均存活,且无不良心脏事件发生。随访时,两组患者的左心室(LV)射血分数均显著改善(IRON组:从53±10%提高到59±9%,p=0.002;CONTROL组:从54±6%提高到57±10%,p=0.005),梗死面积均缩小。IRON组梗死面积的缩小更为显著(IRON组:-10.3±5.4%,而CONTROL组:-7.0±8.4%,p=(此处有误,原文p=0.050,应改为p=0.05)),此外,IRON组患者的心内膜范围和透壁梗死发生率均显著降低,而CONTROL组患者则无此现象。仅IRON组患者的LV收缩末期容积显著降低(从71±25mL降至59±25mL,p=0.002)。
急性STEMI患者静脉注射铁剂似乎与梗死愈合改善及有益的整体左心室重构有关。这些发现连同良好的安全性,使基于USPIO的铁剂给药成为急性MI管理中一种有前景的未来“诊断”和“治疗”辅助解决方案。